Delving into the Latest Updates on AZX-1101 with Synapse

Overview

Basic Info

Drug Type

Enzyme

Synonyms

beta lactamases(AzurRx)

Target

β-lactamase

Mechanism

β-lactamase stimulants(Beta Lactamase stimulants)

Therapeutic Areas

Digestive System DisordersInfectious Diseases

Active Indication-

Inactive Indication

Bacterial InfectionsGastrointestinal Diseases

Originator Organization

AzurRx SAS

Active Organization-

Inactive Organization

Entero Therapeutics, Inc.AzurRx SAS

Drug Highest PhasePendingPreclinical

First Approval Date-

Regulation-

Patients with cystic fibrosis (CF) often develop respiratory tract infections with pathogenic multidrug-resistant organisms (MDROs) such as methicillin-resistant Staphylococcus aureus, and a variety of gram-negative organisms that include Pseudomonas aeruginosa, Burkholderia sp., Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and nontuberculous mycobacteria (NTM). Despite the introduction of new therapies to address underlying cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, MDRO infections remain a problem and novel antimicrobial interventions are still needed. Therapeutic approaches include improving the efficacy of existing drugs by adjusting the dose based on differences in CF patient pharmacokinetics/pharmacodynamics, the development of inhaled formulations to reduce systemic adverse events, and the use of newer beta-lactam/beta-lactamase combinations. Alternative innovative therapeutic approaches include the use of gallium and bacteriophages to treat MDRO pulmonary infections including those with extreme antibiotic resistance. However, additional clinical trials are required to determine the optimal dosing and efficacy of these different strategies and to identify patients with CF most likely to benefit from these new treatment options.

01 Dec 2022·Clinics in Chest Medicine

Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis

Review

Author: Murray, Thomas S ; Koff, Jonathan L ; Stanley, Gail

Patients with cystic fibrosis (CF) often develop respiratory tract infections with pathogenic multidrug-resistant organisms (MDROs) such as methicillin-resistant Staphylococcus aureus, and a variety of gram-negative organisms that include Pseudomonas aeruginosa, Burkholderia sp., Stenotrophomonas maltophilia, Achromobacter xylosoxidans, and nontuberculous mycobacteria (NTM). Despite the introduction of new therapies to address underlying cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction, MDRO infections remain a problem and novel antimicrobial interventions are still needed. Therapeutic approaches include improving the efficacy of existing drugs by adjusting the dose based on differences in CF patient pharmacokinetics/pharmacodynamics, the development of inhaled formulations to reduce systemic adverse events, and the use of newer beta-lactam/beta-lactamase combinations. Alternative innovative therapeutic approaches include the use of gallium and bacteriophages to treat MDRO pulmonary infections including those with extreme antibiotic resistance. However, additional clinical trials are required to determine the optimal dosing and efficacy of these different strategies and to identify patients with CF most likely to benefit from these new treatment options.

26 Oct 2022·Microbiology Spectrum

Imipenem-Relebactam Susceptibility in Enterobacterales Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies)

Article

Author: García-Castillo, María ; Cercenado, Emilia ; Hernández-García, Marta ; Pitart, Cristina ; Tormo, Nuria ; Pinto, Margarida F. ; Alves, Valquíria ; Duarte, Joana ; Sancho, Luísa ; Pássaro, Leonor ; Chaves, Catarina ; Cruz, Hugo ; Bou, Germán ; Díaz-Regañón, Jazmín ; Diogo, José ; Gonçalves, Elsa ; Oliver, Antonio ; Cantón, Rafael ; Ferreira, Rui ; Rodríguez-Lozano, Jesús ; Vieira, Ana Raquel ; Delgado-Valverde, Mercedes ; Melo-Cristino, José ; Ramalheira, Elmano

We comparatively evaluate the in vitro activity of a drug combination consisting of a carbapenem (imipenem) and a novel inhibitor of beta-lactamases (relebactam), a mechanism that destroys beta-lactam antibiotics. We assess the activity against a collection of Enterobacterales clinical isolates recovered from difficult-to-treat infections in patients admitted to different intensive care units in Portugal and Spain.

100 Deals associated with AZX-1101

Login to view more data